Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Schizophrenia Treatment Acceptance Response Trial: a 20-week, Open-label, Multicenter, Randomized Study Comparing the Effect of the "GAIN Acceptance Approach Verses the "Approach-as-usual" in Supporting Patient Acceptance of Long-acting Risperidone (Risperdal� CONSTA�) in Adults With Schizophrenia

NCT00261430 is registered in ClinicalTrials.gov with Janssen, LP as lead sponsor.

NCT NCT00261430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00261430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Schizophrenia Treatment Acceptance Response Trial: a 20-week, Open-label, Multicenter, Randomized Study Comparing the Effect of the "GAIN Acceptance Approach Verses the "Approach-as-usual" in Supporting Patient Acceptance of Long-acting Risperidone (Risperdal� CONSTA�) in Adults With Schizophrenia
Lead sponsor
Janssen, LP
Phase
Phase 4
Overall status
Completed
Start date
Not reported
Completion date
October 31, 2004
Enrollment
650 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia